Provided by Tiger Trade Technology Pte. Ltd.

Cadrenal Therapeutics, Inc.

1.75
+0.210013.64%
Post-market: 1.59-0.1600-9.14%17:54 EDT
Volume:21.43M
Turnover:41.50M
Market Cap:6.24M
PE:-0.36
High:2.29
Open:1.64
Low:1.46
Close:1.54
52wk High:14.64
52wk Low:1.46
Shares:3.57M
Float Shares:3.22M
Volume Ratio:596.36
T/O Rate:664.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8667
EPS(LYR):-6.6394
ROE:-275.16%
ROA:-125.93%
PB:1.53
PE(LYR):-0.26

Loading ...

Cadrenal Therapeutics - no Serious Adverse Events or Deaths Reported with Cad-1005 in Phase 2 Trial

THOMSON REUTERS
·
Jul 13

Cadrenal Therapeutics CMO James Ferguson Resigns, Effective July 31

Reuters
·
Jul 11

Cadrenal Therapeutics CEO, Chairman Quang X. Pham Disposes of 7,400 Common Shares Worth $22,422

Reuters
·
Jul 02

Cadrenal Therapeutics Prices USD 3 Million At-the-market Private Placement of Shares, Warrants

Reuters
·
Jul 01

Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-the-market Under NASDAQ Rules

THOMSON REUTERS
·
Jul 01

Cadrenal Therapeutics - Appoints John P. Sharp as Interim CFO Effective June 25, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 30

Cadrenal Therapeutics - Quang X. Pham Ceases to Serve as Interim CFO - SEC Filing

THOMSON REUTERS
·
Jun 30

Cadrenal Therapeutics Names John P. Sharp Interim CFO, Replacing Quang X. Pham

Reuters
·
Jun 30

Cadrenal Therapeutics Chairman, CEO Quang X. Pham Reports Common Share Disposal Worth $33,807.45

Reuters
·
Jun 27

Cadrenal Therapeutics Chairman, CEO Quang X. Pham Sells USD 39,849 of Common Shares

Reuters
·
Jun 25

NASDAQ Trade Halt Volatility Trading Pause at 11:14 Am

Reuters
·
Jun 24

Cadrenal Therapeutics to Present Late-breaking Cad-1005 Phase 2 HIT Trial Data at ISTH Congress

Reuters
·
Jun 24

Cadrenal Therapeutics Announces Selection of Cad-1005 Phase 2 Study for Late-breaking Oral Presentation at Isth 2026 Congress

THOMSON REUTERS
·
Jun 24

Cadrenal Therapeutics Chairman, CEO and Interim CFO Quang X. Pham disposes of $13,127 in common shares

Reuters
·
Jun 19

Cadrenal plans FDA rare pediatric disease designation filing for tecarfarin in Kawasaki disease

Reuters
·
Jun 18

Cadrenal Therapeutics - to Submit FDA Rare Pediatric Disease Designation Request for Tecarfarin in Kawasaki Disease

THOMSON REUTERS
·
Jun 18

Cadrenal Therapeutics Chairman, CEO Quang X. Pham disposes of USD 70,947 in common shares

Reuters
·
Jun 16

Cadrenal Therapeutics to initiate CAD-1005 trial

TIPRANKS
·
Jun 15

Cadrenal Therapeutics plans Phase 2a trial of CAD-1005 to prevent acute kidney injury in high-risk cardiac surgery patients

Reuters
·
Jun 15

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (Csa-Aki) Clinical Plan to Accelerate Pharma Partnering at Upcoming Bio 2026

THOMSON REUTERS
·
Jun 15